Alamar Biosciences (NASDAQ:ALMR) Sets New 52-Week High on Strong Earnings

Shares of Alamar Biosciences, Inc. (NASDAQ:ALMR) hit a new 52-week high during trading on Tuesday after the company announced better than expected quarterly earnings. The stock traded as high as $32.15 and last traded at $31.94, with a volume of 75588 shares trading hands. The stock had previously closed at $27.99.

The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.14. The company had revenue of $29.43 million during the quarter.

Trending Headlines about Alamar Biosciences

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: Alamar reported second-quarter revenue of $29.43 million, while its adjusted loss of $0.22 per share was better than the analyst consensus loss of $0.36. The earnings beat suggests improving operating execution. Alamar Q2 earnings report
• Positive Sentiment: Management issued 2026 revenue guidance of $116 million to $120 million, above the roughly $113.1 million analyst estimate. The company also outlined plans to place more than 100 instruments and generate over $400,000 in annual pull-through revenue per instrument, indicating confidence in demand for its platform. Alamar 2026 revenue outlook
• Positive Sentiment: Second-quarter revenue reportedly increased 82% year over year, highlighting rapid commercial expansion. Management’s earnings-call commentary also emphasized accelerating instrument adoption and recurring consumables revenue. Alamar Q2 earnings call highlights
• Positive Sentiment: Alamar expanded its global partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures. The collaboration could broaden the use of Alamar’s proteomics technology in Alzheimer’s research and improve the company’s visibility with pharmaceutical and research customers. Alamar global partnership
• Negative Sentiment: Despite the earnings beat and strong growth, Alamar remains unprofitable. The quarterly loss and the absence of a specific profitability target leave investors focused on how quickly revenue growth can translate into improving margins and cash flow.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ALMR. Bank of America assumed coverage on Alamar Biosciences in a research note on Tuesday, May 12th. They issued a “neutral” rating and a $27.00 target price for the company. Wall Street Zen raised Alamar Biosciences to a “hold” rating in a research note on Saturday, April 25th. TD Cowen reiterated a “buy” rating on shares of Alamar Biosciences in a report on Wednesday, July 15th. Stifel Nicolaus set a $32.00 price objective on Alamar Biosciences in a research report on Tuesday. Finally, Zacks Research raised Alamar Biosciences to a “hold” rating in a report on Wednesday, May 13th. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $31.80.

Alamar Biosciences Trading Up 18.8%

The business’s 50 day moving average price is $24.58. The company has a market capitalization of $2.30 billion and a PE ratio of -19.11.

Alamar Biosciences Company Profile

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.